[144] Ascendis Pharma A/S American SEC Filing

Rhea-AI Filing Summary

Form 144 filing for Ascendis Pharma A/S (ASND) shows proposed and recent officer-related sales of American Depositary Shares (ADS). The filing lists a proposed sale of 5,000 ADS through Merrill Lynch on 09/09/2025 with an aggregate market value of $1,018,503.05. The 5,000 ADS were acquired on 09/09/2025 via warrant exercise from Ascendis Pharma A/S and paid for in cash the same day. The filer also reported a sale on 08/13/2025 of 10,000 ADS for gross proceeds of $1,913,224.99. The notice includes the filer’s representation that they are not aware of undisclosed material adverse information about the issuer.

Insights

Securities Analyst

TL;DR: Insider executed warrants and plans a modest sale of 5,000 ADS; recent prior sale of 10,000 ADS was reported.

The filing documents a warrant exercise and immediate intention to sell the resulting 5,000 ADS through Merrill Lynch on 09/09/2025 valued at $1,018,503.05. The prior disposition on 08/13/2025 involved 10,000 ADS with gross proceeds reported as $1,913,224.99. These are transactional disclosures required under Rule 144 and provide transparency on share movements by the named person. The items disclosed are factual and do not include commentary on intent, timing beyond the listed approximate sale date, or any nonpublic operational information.

Corporate Governance Expert

TL;DR: Required compliance filing shows insider selling activity and confirms representation about absence of undisclosed material information.

The form contains the filer's certification that they are unaware of material adverse information not publicly disclosed, and it records both the acquisition via warrant exercise and planned disposition details as required by securities rules. From a governance and disclosure standpoint, the filing appears complete for the transactions listed: broker identity, quantities, values, acquisition method, and payment details are provided. No additional governance issues or omissions are apparent within the text provided.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
American Depositary Shares	Merrill Lynch 225 Liberty St Floor 37 New York NY 10281	5000	1018503.05	60454589	09/09/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
American Depositary Shares	09/09/2025	Warrant exercise	Ascendis Pharma A/S			5000	09/09/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Flemming Jensen TUBORG BOULEVARD 12 HELLERUP G7 00000	American Depositary Shares	08/13/2025	10000	1913224.99

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the ASND Form 144 disclose about the planned sale?

The filing shows a proposed sale of 5,000 ADS via Merrill Lynch on 09/09/2025 with an aggregate market value of $1,018,503.05.

How were the 5,000 ADS acquired according to the filing?

The 5,000 ADS were acquired on 09/09/2025 through a warrant exercise from Ascendis Pharma A/S and paid for in cash the same day.

Did the filer sell any Ascendis ADS recently?

Yes. The filing reports a sale on 08/13/2025 of 10,000 ADS for gross proceeds of $1,913,224.99.

Which broker is named for the proposed sale in the Form 144?

The proposed sale lists Merrill Lynch, 225 Liberty St, Floor 37, New York, NY as the broker.

Does the filer assert awareness of undisclosed material information?

Yes. By signing, the person represents they do not know of any material adverse information about the issuer that has not been publicly disclosed.